Compare · AYLA vs NPT
AYLA vs NPT
Side-by-side comparison of Ayala Pharmaceuticals Inc. (AYLA) and Texxon Holding Limited (NPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYLA and NPT operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- NPT carries a market cap of $39.5M.
- NPT has hit the wire 1 time in the past 4 weeks while AYLA has been quiet.
- AYLA has more recent analyst coverage (5 ratings vs 0 for NPT).
- Company
- Ayala Pharmaceuticals Inc.
- Texxon Holding Limited
- Price
- -
- -
- Market cap
- -
- $39.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 5
- 0
Ayala Pharmaceuticals Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Latest AYLA
- SEC Form 3 filed by new insider Martell Bridget A
- SEC Form 3 filed by new insider Orbach Pini
- SEC Form 3 filed by new insider Golan Roy
- SEC Form 10-K filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.
- Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets
- SEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company
Latest NPT
- SEC Form NT 20-F filed by Texxon Holding Limited
- Texxon Holding Limited Announces Commencement of Operations at Henan Polystyrene Production Facility, A Milestone in Manufacturing Expansion Strategy
- SEC Form 6-K filed by Texxon Holding Limited
- Texxon Holding Limited Announces Unaudited Financial Results for the First Half of Fiscal Year 2026
- SEC Form 6-K filed by Texxon Holding Limited
- SEC Form 6-K filed by Texxon Holding Limited
- Texxon Holding Limited Announces Annual General Meeting
- SEC Form 3 filed by new insider Xu Hui
- SEC Form 3 filed by new insider Huang Jian (Hanke)
- SEC Form 3 filed by new insider Qin Lei